Brief: Oramed Subsidiary Oravax Reports First Participant Enrolled in Oral COVID-19 Vaccine Trial
14/12/2021 13:15
Dec 14 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED SUBSIDIARY ORAVAX ANNOUNCES FIRST PARTICIPANT
ENROLLED IN
PHASE 1 ORAL COVID-19 VACCINE TRIAL IN SOUTH AFRICA
Source text for Eikon: ID:nPn2yxvlha
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results